BioGend Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 2.02 million compared to TWD 0.589 million a year ago. Net loss was TWD 39.24 million compared to TWD 44.27 million a year ago. Basic loss per share from continuing operations was TWD 0.39 compared to TWD 0.48 a year ago. Diluted loss per share from continuing operations was TWD 0.39 compared to TWD 0.48 a year ago. For the nine months, sales was TWD 4.46 million compared to TWD 1.07 million a year ago. Net loss was TWD 124.34 million compared to TWD 114.38 million a year ago. Basic loss per share from continuing operations was TWD 1.23 compared to TWD 1.33 a year ago. Diluted loss per share from continuing operations was TWD 1.23 compared to TWD 1.33 a year ago.